The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer

Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

[1]  I. Ganly,et al.  Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy , 2011, Cancer.

[2]  J. Griggs,et al.  Use of radioactive iodine for thyroid cancer. , 2011, JAMA.

[3]  J. Tward,et al.  Overall and cause‐specific survival for patients undergoing lobectomy, near‐total, or total thyroidectomy for differentiated thyroid cancer , 2011, Head & neck.

[4]  A. Sanabria,et al.  Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer , 2011, Head & neck.

[5]  F. Jegoux,et al.  Pattern of lateral neck metastases in N0 papillary thyroid carcinoma , 2011, BMC Cancer.

[6]  I. Sugitani,et al.  Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes , 2010, World Journal of Surgery.

[7]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[8]  J. Jonklaas,et al.  Recurrence after treatment of micropapillary thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[9]  Amy Y. Chen,et al.  Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005 , 2009, Cancer.

[10]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  E. Choi,et al.  Predictive Factors For Ipsilateral or Contralateral Central Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma , 2009, Annals of surgery.

[12]  L. Kowalski,et al.  Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. , 2009, Archives of otolaryngology--head & neck surgery.

[13]  S. Devesa,et al.  Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005 , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  C. Silver,et al.  Paratracheal node dissection for well-differentiated cancer of the thyroid: indications, technique and results. , 2008, Auris, nasus, larynx.

[15]  T. Sebo,et al.  Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.

[16]  A. Gafni,et al.  An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[17]  E. Livingston,et al.  Trends in thyroid cancer demographics and surgical therapy in the United States. , 2007, Surgery.

[18]  Tae Yong Kim,et al.  Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. , 2007, Endocrine journal.

[19]  J. Jonklaas,et al.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[20]  Yasuhiro Ito,et al.  Clinical Significance of Lymph Node Metastasis of Thyroid Papillary Carcinoma Located in One Lobe , 2006, World Journal of Surgery.

[21]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[22]  R. Tsang,et al.  Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years , 2005, Clinical endocrinology.

[23]  E. Baudin,et al.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  J. Watkinson,et al.  The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.

[25]  Sendia Kim,et al.  Predicting outcome and directing therapy for papillary thyroid carcinoma. , 2004, Archives of surgery.

[26]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[27]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[28]  M. Ringel,et al.  The Role of Radioactive Iodine in Salivary Gland Dysfunction , 2000, Ear, nose, & throat journal.

[29]  C. Kirsch,et al.  Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  E. Mazzaferri.  Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.

[31]  J. Shah,et al.  Risk group stratification and prognostic factors in papillary carcinoma of thyroid , 1996, Annals of Surgical Oncology.

[32]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[33]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[34]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[35]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[36]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[37]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[38]  S. Jhiang,et al.  Differentiated thyroid cancer long-term impact of initial therapy. , 1995, Transactions of the American Clinical and Climatological Association.

[39]  L. Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.